NCT02135133 - A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

October 6, 2020

Study Completion Date

October 6, 2020

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Interventions

DRUG

Idelalisib

150 mg BID Oral Daily

DRUG

Ofatumumab

Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Isreal Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston